|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Reduction in human fetal umbilical placental vascular resistance by glyceryl triuitrate显示文摘 | Warwick RH Giles LE Parlior CM | 1992 | Lancet1992，340，30： | 1 |
| 2 | Reduction in human fetal umbilical placental vascular resistance by glyceryl triuitrat显示文摘 | warwick RH Giles LE Parlior CM etal | 1992 | Lancet1992，340，30： | 1 |
| 3 | Niiotinib (formerly AMN107) , a high selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia显示文摘 | LE COUTRE P OTTMANN OCG GILES F | 2008 | Blood2008，111，4： | 1 |
| 4 | The influence of dose of angiotensin I-converting enzyme inhibitor on systolic blood pressure variability in heart failure:a substudy of the Assessment of Treatment with Lisinopril and Survival in heart failure (ATLAS)trial显示文摘 | Giles TD Kerut EK Roffidal LE | 2001 | Blood Press Monit2001，，2： | 1 |
| 5 | Nilolinib(formerlyAMN107), a high selective BCR-ABL tyrosine kinase inhibitor, is active in patients with iraatinib-resistant orintolerant accelerated phase chronic myelogenous leukemia 显示文摘 | Le Coutre P Ottmann OG Giles F | 2008 | Blood2008，111，4： | 1 |
| 6 | Nilntinib (formerly AMN 107), a highly selective bcr abl tyrosine kinase inhibitor, is active in patients with imatinib-resistant or intolerant accelerated phase chronic myelogenous leukemia显示文摘 | Le Coutre P Ottmann OG Giles F etal | 2008 | Blood2008，110，4： | 1 |
| 7 | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia显示文摘 | LE COUTRE P OTTMANN O G GILES F | 2008 | Blood2008，111，： | 1 |
| 8 | Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study 显示文摘 | Giles F J le Coutre PD Pinilla-Ibarz J | 2013 | Leukemia2013，27，1： | 1 |
| 9 | Nilotinib (formerly AMN107), a highly selective BCR ABL tyrosine kinase inhibitor, is active in patients with imatinih-resistant or-intolerant accelerated-phase chronicmyelogenous leukemi显示文摘 | LE COUTRE P OTTMANN O G GILES F | 2008 | Blood2008，111，： | 1 |
| 10 | Nilotinib is effec- tive in imatinib-resistant or -intolerant patients with chronic my- eloid leukemia in blastic phase 显示文摘 | Giles FJ Kantarjian HM le Coutre PD | 2012 | Leukemia2012，26，5： | 1 |
| 11 | Nilotinib formerly AMN107,a highly selective BCR-ABL tyrosine kinase inhibitor,is activein patients with imatinib resistant or intolerant accelerated-phasechronic myelogenous leukemia显示文摘 | Le Coutre P Ottmann O G Giles F | 2008 | Blood2008，1114，1： | 1 |
| 12 | Nilotinib (formerly AMN107),a highly selective BCR-ABL tyrosine kinase inhibitor,is active in patients with irnatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia显示文摘 | LE COUTRE P OTTMANN OG GILES F | 2008 | Blood2008，111，4： | 1 |
| 13 | Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance:24-month follow- up results 显示文摘 | le COUTRE P D GILES F J HOCHHAUS A | 2012 | Leukemia2012，26，6： | 1 |
| 14 | Nilotinib is effective in imatinib resistant or-in- tolerant patients with chronic myeloid leukemia in blastic phase显示文摘 | GILES F J KANTARJIAN H M LE COUTRE P D | 2012 | Leukemia2012，26，： | 1 |
| 15 | Nilotinib (formerly AMNI07), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia 显示文摘 | LE COUTRE P OTTMANN OG GILES F | 2008 | Blood2008，111，4： | 1 |
| 16 | Nilotinib(formerly AMN107), a highly selective bcr-abl tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated- phase chronic myelogenous leukemia显示文摘 | Le Coutre P Ottmann OG Giles F | 2008 | Blood2008，110，4： | 1 |
| 17 | Nilotinib a highly selective BCR- ABL tyrosine kinase inhibitor,is active in patients with imatinib - resistant or intolerant acceleratedphase chronic myelogenous leukemia 显示文摘 | Le Coutre P Ottmann OG Giles F | 2008 | Blood2008，111，4： | 1 |
| 18 | Nilotinib inchronic myeloid leukemia patients in accelerated phase(CML-AP)with imatinib(IM)resistance or intolerance:Longer follow-up results of a phaseⅡstudy显示文摘 | le Coutre PD Giles FJ Hochhaus A | 2009 | J ClinOncol2009，27，15： | 1 |
| 19 | Nilotinib (formerlyAMN107 ), a highly selective BCR-ABL tyrosine kinase inhibitor, isactive in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia 显示文摘 | le Coutre P Ottmann OG Giles F | 2008 | Blood2008，111，4： | 1 |
| 20 | Nilotinib( formerly AMNI07 ), a highly selective BCR - ABL tyrosine ki- nase inhibitor,is active in patients with imatinib-resistant or intolerant accelerated -phase chronic myelogenous leukemia 显示文摘 | le Coutre P Ottmann OG Giles F | 2008 | Blood2008，111，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员